HeartBeam Appoints Robert Eno as CEO to Lead FDA Clearance and Commercialization Efforts

HeartBeam has appointed Robert Eno as its new chief executive officer, effective October 21, 2024. Eno, who joined the company as President in January 2023, will focus on guiding HeartBeam through FDA 510(k) clearance and preparing for commercialization of its transformative vector-based cardiac technology. Founder and current CEO, Dr. Branislav Vajdic, will transition to president, concentrating on advancing the company's innovative technology and artificial intelligence applications.

HeartBeam's technology captures the heart's electrical signals in three dimensions and aims to revolutionize cardiac care with a credit card-sized device capable of synthesizing a 12-lead ECG. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care—all outside of a medical facility, thus redefining the future of cardiac health management.

The company holds 13 U.S. and 4 international-issued patents related to technology enablement. With extensive experience in MedTech and strategic growth, Eno is expected to position the company for continued success. The latest news and updates relating to BEAT are available in the company's newsroom at https://ibn.fm/BEAT. For more information about HeartBeam's transformative cardiac technology, visit https://www.HeartBeam.com.

This leadership transition comes at a critical juncture as the company prepares for regulatory milestones and market entry. The appointment signals HeartBeam's commitment to leveraging experienced leadership to navigate the complex medical device regulatory landscape while advancing technology that could significantly impact how cardiac conditions are monitored and managed outside traditional healthcare settings.